Virios Therapeutics Llc

About Virios Therapeutics Llc

Virios Therapeutics (NASDAQ: VIRI) is a biotech firm focused on developing novel antiviral therapies for fibromyalgia and related conditions based on the hypothesis that these illnesses are triggered by activated herpes virus. Based in the U.S., Virios is dedicated to advancing their lead product candidate, IMC-1, through clinical trials to address unmet needs in chronic pain management. The company aims to leverage its proprietary technology to modulate disease-related viruses and improve patient outcomes, providing innovative solutions for hard-to-treat disorders. With its robust research initiatives and commitment to groundbreaking treatments, Virios Therapeutics strives to make meaningful contributions to the healthcare landscape.

What is Virios Therapeutics Llc known for?

Snapshot

2012

Year founded

Employees

Alpharetta, United States

Head office

Loading Map...

Operations

All Locations

Alpharetta, US

Products and/or services of Virios Therapeutics Llc

IMC-1: A proprietary combination antiviral therapy targeting fibromyalgia by suppressing herpes virus activation, aimed at reducing pain and improving patient quality of life.
Chronic Fatigue Syndrome Study: Researching the potential effects of antiviral therapies on chronic fatigue syndrome to assess symptomatic relief and improve management strategies.
Antiviral Combinational Research: Investigating the efficacy of synergistic antiviral combinations to treat chronic diseases associated with herpes viral activity.
HSV-Related Disease Exploration: Developing therapies targeting conditions impacted by herpes simplex virus to broaden the application of their antiviral research.
Collaborative Partnerships: Engaging in partnerships with research institutions to explore innovative antiviral approaches and expand therapeutic capabilities.
Intellectual Property Exploration: Actively strengthening their patent portfolio to protect discoveries around antiviral therapies and enhance competitive advantage.